[go: up one dir, main page]

FI905983L - Aminosyraderivat. - Google Patents

Aminosyraderivat. Download PDF

Info

Publication number
FI905983L
FI905983L FI905983A FI905983A FI905983L FI 905983 L FI905983 L FI 905983L FI 905983 A FI905983 A FI 905983A FI 905983 A FI905983 A FI 905983A FI 905983 L FI905983 L FI 905983L
Authority
FI
Finland
Prior art keywords
amino acid
acid derivatives
derivatives
amino
acid
Prior art date
Application number
FI905983A
Other languages
English (en)
Other versions
FI905983A0 (fi
FI100883B (fi
Inventor
Joseph Armstrong Martin
Sally Redshaw
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to FI973895A priority Critical patent/FI973895A0/fi
Publication of FI905983A0 publication Critical patent/FI905983A0/fi
Publication of FI905983L publication Critical patent/FI905983L/fi
Application granted granted Critical
Publication of FI100883B publication Critical patent/FI100883B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Confectionery (AREA)
  • Cleaning Or Clearing Of The Surface Of Open Water (AREA)
  • Measurement Of Force In General (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI905983A 1989-12-11 1990-12-04 Menetelmä 2-£3(S)-£(L-asparaginyyli)amino|-2(R)-hydroksi-4-fenyylibuty yli|-N-tert-butyylidekahydro-(4aS,8aS)-isokinoliini-3(S)-karboksiamidi johdannaisten valmistamiseksi FI100883B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI973895A FI973895A0 (fi) 1989-12-11 1990-12-04 2-(3(S)-((L-asparaginyyli)amino)-2(R)-hydroksi-4-fenyylibutyyli)-N-tert-butyylidekahydro-(4aS,8aS)-isokinoliini-3(S)-karboksiamidijohdannaiset

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8927913 1989-12-11
GB898927913A GB8927913D0 (en) 1989-12-11 1989-12-11 Amino acid derivatives
SG120493 1993-11-02
SG120493A SG120493G (en) 1989-12-11 1993-11-02 N-tert-Butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl) isoquinoline-3-carboxamide and asparaginyl derivatives thereof

Publications (3)

Publication Number Publication Date
FI905983A0 FI905983A0 (fi) 1990-12-04
FI905983L true FI905983L (fi) 1991-06-12
FI100883B FI100883B (fi) 1998-03-13

Family

ID=26296345

Family Applications (2)

Application Number Title Priority Date Filing Date
FI905983A FI100883B (fi) 1989-12-11 1990-12-04 Menetelmä 2-£3(S)-£(L-asparaginyyli)amino|-2(R)-hydroksi-4-fenyylibuty yli|-N-tert-butyylidekahydro-(4aS,8aS)-isokinoliini-3(S)-karboksiamidi johdannaisten valmistamiseksi
FI973895A FI973895A0 (fi) 1989-12-11 1990-12-04 2-(3(S)-((L-asparaginyyli)amino)-2(R)-hydroksi-4-fenyylibutyyli)-N-tert-butyylidekahydro-(4aS,8aS)-isokinoliini-3(S)-karboksiamidijohdannaiset

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI973895A FI973895A0 (fi) 1989-12-11 1990-12-04 2-(3(S)-((L-asparaginyyli)amino)-2(R)-hydroksi-4-fenyylibutyyli)-N-tert-butyylidekahydro-(4aS,8aS)-isokinoliini-3(S)-karboksiamidijohdannaiset

Country Status (48)

Country Link
US (1) US5196438A (fi)
EP (1) EP0432695B1 (fi)
JP (1) JP2807093B2 (fi)
KR (1) KR970005912B1 (fi)
CN (2) CN1066329C (fi)
AT (1) ATE122661T1 (fi)
AU (1) AU634319B2 (fi)
BG (1) BG51452A3 (fi)
BR (1) BR9006264A (fi)
CA (1) CA2030433C (fi)
CU (1) CU22305A3 (fi)
CZ (1) CZ280558B6 (fi)
DE (2) DE69019481T2 (fi)
DK (1) DK0432695T3 (fi)
DZ (1) DZ1467A1 (fi)
EG (1) EG19722A (fi)
ES (1) ES2072959T3 (fi)
FI (2) FI100883B (fi)
GB (2) GB8927913D0 (fi)
GR (1) GR3017114T3 (fi)
HK (1) HK129093A (fi)
HR (1) HRP930341B1 (fi)
HU (2) HU207298B (fi)
ID (1) ID1018B (fi)
IE (1) IE67523B1 (fi)
IL (1) IL96550A (fi)
IN (1) IN172553B (fi)
IS (1) IS1803B (fi)
LT (1) LT3682B (fi)
LU (1) LU90014I2 (fi)
LV (1) LV5738B4 (fi)
MA (1) MA22014A1 (fi)
MC (1) MC2195A1 (fi)
MT (1) MTP1075B (fi)
MW (1) MW8890A1 (fi)
MX (1) MX173630B (fi)
NL (1) NL970013I2 (fi)
NO (1) NO176566C (fi)
OA (1) OA09334A (fi)
PL (1) PL165225B1 (fi)
PT (1) PT96145B (fi)
RO (1) RO107942B1 (fi)
RU (1) RU2071470C1 (fi)
SG (1) SG120493G (fi)
SI (1) SI9012315B (fi)
SK (1) SK280249B6 (fi)
ZA (1) ZA909743B (fi)
ZW (1) ZW17490A1 (fi)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) * 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
USH1649H (en) 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
US5430041A (en) * 1991-05-10 1995-07-04 Hoffmann-La Roche Inc. Amino acid derivatives having antiviral activity
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
EP0541168B1 (en) * 1991-11-08 1998-03-11 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
BR9306058A (pt) 1992-03-11 1997-11-18 Narhex Ltd Derivados de amina de hidrocarbonetos oxo- e hidroxi- substituidos
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
ATE116640T1 (de) * 1992-03-13 1995-01-15 Bio Mega Boehringer Ingelheim Substituierte pipecoline-säurederivate als hiv- protease-hemmer.
CA2136312A1 (en) * 1992-05-21 1993-11-25 Michael Clare Retroviral protease inhibitors
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
KR100296463B1 (ko) 1992-08-25 2001-10-24 죤 에이치. 뷰센 레트로바이러스프로테아제저해제로서유용한히드록시에틸아미노술폰아미드
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5783701A (en) 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
TW372972B (en) * 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
US5380849A (en) * 1992-11-09 1995-01-10 Merck & Co., Inc. Process for optically pure decahydroisoqiunolines
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
WO1994017096A1 (en) * 1993-01-17 1994-08-04 Schering Corporation Peptides having anti-hiv activity
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
ES2125077T3 (es) 1993-07-15 1999-02-16 Hoffmann La Roche Procedimiento de obtencion de una n-tert-butilamida.
AU8074894A (en) * 1994-02-02 1995-08-21 Eli Lilly And Company Hiv protease inhibitors and intermediates
ES2139195T3 (es) * 1994-03-07 2000-02-01 Vertex Pharma Derivados de sulfonamidas como inhibidores de la aspartil-proteasa.
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5470979A (en) * 1994-07-01 1995-11-28 American Cyanamid Company Asymmetric synthesis of bicyclic amino acid esters
US5523463A (en) * 1994-09-23 1996-06-04 Hoffmann-La Roche Inc. Method of producing halogenated and alpha-aminoalchohols
US5591885A (en) * 1994-09-23 1997-01-07 Hoffman-La Roche Inc. Process for the preparation of halogenated α-aminoketone compounds
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
BR9610842A (pt) * 1995-06-06 1999-07-13 Hoffmann La Roche Composição farmacêutica compreendendo um inibidor de proteinase e um monoglicerídeo
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
AU759386B2 (en) * 1995-06-29 2003-04-10 Abbvie Inc. Use of Ritonavir (ABT-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS
CA2235394A1 (en) 1995-11-13 1997-05-22 Gerard Voerman Anti-viral isolates obtainable from leeches
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5587481A (en) * 1996-02-20 1996-12-24 The Monsanto Company Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide
US5914404A (en) * 1996-08-09 1999-06-22 Hoffmann-La Roche Inc. Process for the preparation of quinargine
EP0823424A1 (de) * 1996-08-09 1998-02-11 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Chinargin
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ATE236880T1 (de) 1996-12-11 2003-04-15 Hoffmann La Roche Verfahren zur herstellung gemischter anhydride
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
FR2779653B1 (fr) * 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
NZ508855A (en) * 1998-06-19 2003-10-31 Vertex Pharma Sulfonamide inhibitors of HIV aspartyl protease
CA2347001A1 (en) * 1998-10-21 2000-04-27 Fujisawa Pharmaceutical Co., Ltd. Vitreous form of known bradykinin antagonist
KR100277723B1 (ko) 1998-12-14 2001-01-15 남창우 광학적으로 순수한 데카하이드로이소퀴놀린카르복사미드의 연속제조공정
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US6765019B1 (en) * 1999-05-06 2004-07-20 University Of Kentucky Research Foundation Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
HU229501B1 (hu) * 1999-06-04 2014-01-28 Abbvie Inc HIV proteáz gátló vegyületet tartalmazó gyógyszerkészítmények
EP1202626A4 (en) * 1999-07-20 2002-10-30 Merck & Co Inc ALPHA HYDROXY GAMMA (CARBOZYCLIC OR HETEROCYCLICALLY SUBSTITUTED) AMINOCARBONYLALKANAMIDE DERIVATIVES AND THEIR USE
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
US6642237B1 (en) 1999-11-24 2003-11-04 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof
IT1313682B1 (it) * 1999-11-25 2002-09-09 Archimica Spa Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
EP1917958B1 (en) 2000-01-19 2012-06-13 Abbott Laboratories Improved HIV protease inhibitors pharmaceutical formulations
AU2001259817A1 (en) 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
IT1318986B1 (it) * 2000-10-09 2003-09-19 Archimica S P A Ora Clariant L Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
GB0028483D0 (en) 2000-11-22 2001-01-10 Hoffmann La Roche Hydroxyethylamine HIV protease inhibitors
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
EP1463807A4 (en) 2001-12-19 2006-04-12 Bristol Myers Squibb Co FORMATHYDROGENASE FROM PICHIA PASTORIS AND USES THEREOF
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
AU2003276047A1 (en) * 2002-06-17 2003-12-31 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
EA015349B1 (ru) * 2003-07-11 2011-06-30 Ф. Хоффманн-Ля Рош Аг Твёрдая разовая пероральная фармацевтическая дозированная форма саквинавирмезилата и способ её изготовления
EP1604662A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus
HRP20070078A2 (hr) 2004-07-27 2007-05-31 Gilead Sciences Fosfonatni analozi spojeva koji inhibiraju hiv
WO2006134612A1 (en) * 2005-06-16 2006-12-21 Hetero Drugs Limited A process for the preparation of saquinavir using novel intermediate
CN102816111B (zh) 2007-03-12 2014-08-06 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
NZ582089A (en) * 2007-06-29 2013-01-25 Gilead Sciences Inc Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
TW200914011A (en) * 2007-06-29 2009-04-01 Gilead Sciences Inc Therapeutic compositions and methods
US20100093811A1 (en) * 2007-09-25 2010-04-15 Coburn Craig A Hiv protease inhibitors
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
SG172060A1 (en) 2008-12-09 2011-07-28 Gilead Sciences Inc Modulators of toll-like receptors
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
EA201100851A1 (ru) * 2008-12-23 2012-04-30 Фармассет, Инк. Аналоги нуклеозидов
EA019341B1 (ru) * 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Фосфорамидаты нуклеозидов
JP2012528160A (ja) 2009-05-27 2012-11-12 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖプロテアーゼ阻害薬
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
EP2632895B1 (en) 2010-10-28 2018-10-03 Merck Canada Inc. Hiv protease inhibitors
EP2392926A1 (en) 2011-02-09 2011-12-07 Roche Diagnostics GmbH Urinary biomarkers in HIV infected subjects
US9133157B2 (en) 2011-10-26 2015-09-15 Merck Canada Inc. HIV protease inhibitors
US9233943B2 (en) 2012-01-10 2016-01-12 Council Of Scientific & Industrial Research Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir
BR112015005347A2 (pt) 2012-09-11 2017-08-08 Merck Sharp & Dohme Corp E Merck Canada Inc composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
US9834526B2 (en) 2013-12-19 2017-12-05 Merck Sharp & Dohme Corp. HIV protease inhibitors
US9737545B2 (en) 2013-12-19 2017-08-22 Merck Sharp & Dohme Corp. HIV protease inhibitors
US9994587B2 (en) 2014-03-06 2018-06-12 Merck Sharp & Dohme Corp. HIV protease inhibitors
US10138255B2 (en) 2014-03-10 2018-11-27 Merck Sharp & Dohme Corp. Piperazine derivatives as HIV protease inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN113577081A (zh) 2014-07-11 2021-11-02 吉利德科学公司 用于治疗hiv的toll样受体调节剂
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
JP2018527366A (ja) 2015-09-15 2018-09-20 ギリアード サイエンシーズ， インコーポレイテッド ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933968A (en) * 1960-10-26 1963-08-14 May & Baker Ltd New phthalimide derivatives
US4123543A (en) * 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
US3901897A (en) * 1972-10-05 1975-08-26 Squibb & Sons Inc 1,2,3,4,4a,5,6,7-octahydro-7-aryl-isoquinolines and derivatives thereof
US4329473A (en) * 1979-06-01 1982-05-11 Almquist Ronald G Oxoalkanoic acid derivatives as inhibitors of angiotensin converting enzyme
SE421551B (sv) * 1980-03-26 1982-01-04 Sandvik Ab Borrverktyg for rotations- och/eller slagborrning
US4470973A (en) * 1982-07-19 1984-09-11 E. R. Squibb & Sons, Inc. Substituted peptide compounds
US4812442A (en) * 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AT383762B (de) * 1985-12-23 1987-08-25 Plansee Metallwerk Verfahren zur herstellung mehrkomponentiger, kongruent erschmelzender lotmaterialien
CA1286989C (en) * 1985-12-26 1991-07-30 A. Arthur Gottlieb Immunoamplifiers and related compositions
WO1988000939A1 (fr) * 1986-07-25 1988-02-11 Banyu Pharmaceutical Co., Ltd. Derives d'amino-alcools optiquement actifs et procede pour leur preparation
US4851387A (en) * 1986-10-14 1989-07-25 Banyu Pharmaceutical Co., Ltd. 5-substituted amino-4-hydroxy-pentanoic acid derivatives and their use
US4863905A (en) * 1987-02-04 1989-09-05 Warner-Lambert Company Renin inhibitors II
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3717631A1 (de) * 1987-05-26 1988-12-15 Merck Patent Gmbh Aminosaeurederivate
DE3733296A1 (de) * 1987-10-02 1989-04-20 Merck Patent Gmbh Aminosaeurederivate
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
DE4033062A1 (de) * 1990-10-18 1992-04-23 Merck Patent Gmbh Aminosaeurederivate
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols

Also Published As

Publication number Publication date
GB2239016B (en) 1993-08-04
CA2030433C (en) 1997-10-21
IE904453A1 (en) 1991-06-19
FI905983A0 (fi) 1990-12-04
SK576590A3 (en) 1999-10-08
AU634319B2 (en) 1993-02-18
AU6787690A (en) 1991-06-13
HU908076D0 (en) 1991-06-28
FI973895A7 (fi) 1997-10-06
FI100883B (fi) 1998-03-13
EP0432695A2 (en) 1991-06-19
ZW17490A1 (en) 1992-06-17
HK129093A (en) 1993-12-03
PT96145A (pt) 1991-09-30
DE69019481T2 (de) 1995-11-09
PL165225B1 (pl) 1994-11-30
EP0432695A3 (en) 1991-12-18
SI9012315A (en) 1997-10-31
MX23619A (es) 1993-10-01
EG19722A (en) 1996-01-31
NO905322D0 (no) 1990-12-10
NL970013I2 (nl) 1997-09-01
KR910011894A (ko) 1991-08-07
HRP930341B1 (en) 1998-12-31
GR3017114T3 (en) 1995-11-30
SK280249B6 (sk) 1999-10-08
BG51452A3 (bg) 1993-05-14
GB8927913D0 (en) 1990-02-14
HUT56073A (en) 1991-07-29
CZ280558B6 (cs) 1996-02-14
NL970013I1 (nl) 1997-05-01
CN1138983A (zh) 1997-01-01
IE67523B1 (en) 1996-04-03
DE69019481D1 (de) 1995-06-22
IL96550A0 (en) 1991-09-16
CN1052482A (zh) 1991-06-26
CZ576590A3 (en) 1995-11-15
DK0432695T3 (da) 1995-09-11
HU211342A9 (en) 1995-11-28
FI973895L (fi) 1997-10-06
SI9012315B (sl) 1998-06-30
MTP1075B (en) 1991-07-31
MX173630B (es) 1994-03-18
HRP930341A2 (en) 1994-10-31
CN1066329C (zh) 2001-05-30
NO176566B (no) 1995-01-16
ID1018B (id) 1996-10-18
FI973895A0 (fi) 1997-10-06
SG120493G (en) 1994-01-21
DZ1467A1 (fr) 2004-09-13
IL96550A (en) 1995-03-15
PT96145B (pt) 1998-04-30
US5196438A (en) 1993-03-23
EP0432695B1 (en) 1995-05-17
MW8890A1 (en) 1991-03-13
PL288201A1 (en) 1991-09-09
JPH03255076A (ja) 1991-11-13
OA09334A (fr) 1992-09-15
LT3682B (en) 1996-01-25
CA2030433A1 (en) 1991-06-12
CN1034805C (zh) 1997-05-07
ZA909743B (en) 1991-08-28
MA22014A1 (fr) 1991-07-01
BR9006264A (pt) 1991-09-24
ES2072959T3 (es) 1995-08-01
DE19675051I2 (de) 2001-04-12
LV5738A4 (lv) 1996-08-20
HU207298B (en) 1993-03-29
LV5738B4 (lv) 1996-12-20
NO176566C (no) 1995-04-26
IS1803B (is) 2002-02-26
LTIP862A (en) 1995-03-27
RU2071470C1 (ru) 1997-01-10
MC2195A1 (fr) 1992-10-05
ATE122661T1 (de) 1995-06-15
JP2807093B2 (ja) 1998-09-30
IN172553B (fi) 1993-09-25
IS3651A7 (is) 1991-06-12
NO905322L (no) 1991-06-12
CU22305A3 (es) 1995-01-31
KR970005912B1 (en) 1997-04-22
GB2239016A (en) 1991-06-19
GB9026776D0 (en) 1991-01-30
RO107942B1 (ro) 1994-01-31
LU90014I2 (fr) 1997-01-31

Similar Documents

Publication Publication Date Title
FI905983L (fi) Aminosyraderivat.
NO901399L (no) Aminosyrederivater.
DE68915207D1 (de) Aminosäure-Derivate.
FI891006A7 (fi) Aminosyraderivat.
DE59008394D1 (de) Aminosäureamid-Derivate.
NO903832L (no) Aminosyrederivater.
NO901033D0 (no) Aminosyrederivater.
FI920420A7 (fi) Aminosyraderivat.
DE122005000012I1 (de) N-(Pyrrolo(2-3-d)pyrimidin-3-ylacyl)-Glutamins{urederivate.
FI884598A7 (fi) Aminosyraderivat.
DE3787657D1 (de) Aminosäure-Derivate.
FI892362L (fi) Buten- eller propensyraderivat.
NO901533D0 (no) Aminosyrederivater.
FI900024A7 (fi) Pyrrolylfenyl-substituerade hydroxamsyraderivat.
NO890635L (no) Reninhemmende aminosyrederivater.
FI913179A7 (fi) Aminosyraderivat.
FI891761L (fi) Aminosyraderivat.
FI906104L (fi) Naftylsulfonylalkansyraderivat.
NO892728L (no) Aminoalkyl-aminokarbonyl-aminodiolaminosyre derivater somanti-hypertensive midler.
DE69018816D1 (de) Aminosäurederivate.
NO901519D0 (no) Aminosyrederivater.
DE59002430D1 (de) Cyclopropanoylaminosäureamid-Derivate.
ATE105549T1 (de) Aminosaeure-derivate.
ATE95518T1 (de) Aminosaeure-derivate.
DK564988D0 (da) Aminosyrederivater

Legal Events

Date Code Title Description
FG Patent granted

Owner name: F. HOFFMANN - LA ROCHE AG